Upholding the principles of autonomy, beneficence, and justice in phase I clinical trials
- PMID: 23457003
- PMCID: PMC3607517
- DOI: 10.1634/theoncologist.2013-0014
Upholding the principles of autonomy, beneficence, and justice in phase I clinical trials
Abstract
This commentary discusses the importance of maintaining the three core principles of autonomy, beneficence, and justice in phase I clinical trials.
Conflict of interest statement
Disclosures of potential conflicts of interest may be found at the end of this article.
Comment on
-
Compliance in early-phase cancer clinical trials research.Oncologist. 2013;18(3):308-13. doi: 10.1634/theoncologist.2012-0260. Epub 2013 Mar 1. Oncologist. 2013. PMID: 23457001 Free PMC article. Review.
References
-
- Garcia VM, Cassier PA, de Bono J. Parallel anticancer drug development and molecular stratification to qualify predictive biomarkers: Dealing with obstacles hindering progress. Cancer Discov. 2011;1:207–212. - PubMed
-
- U.S Department of Health and Human Services. The Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research. [Accessed February 15, 2013]. Available at http://www.hhs.gov/ohrp/humansubjects/guidance/belmont.html.
-
- Horstmann E, McCabe MS, Grochow L, et al. Risks and benefits of phase 1 oncology trials, 1991 through 2002. N Engl J Med. 2005;352:895–904. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical